Scorpion Therapeutics was founded to broaden the reach and impact of precision medicine to more people with cancer. The company is integrating cutting-edge technologies across target discovery, medicinal chemistry, and translational medicine to deliver Precision Oncology 2.0. Scorpion's experienced leadership team is executing a fit-to-purpose model to efficiently unlock the next generation of precision oncology.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 10/26/20 | $108,000,000 | Series A |
Abingworth Atlas Venture  Omega Funds Partners HealthCare Innovation Vida Ventures | undisclosed |
